AbbVie Inc (ABBV)vsAstrana Health Inc (ASTH)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ASTH
Astrana Health Inc
$37.99
+0.37%
HEALTHCARE · Cap: $1.87B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1681% more annual revenue ($62.82B vs $3.53B). ABBV leads profitability with a 5.8% profit margin vs 0.9%. ASTH trades at a lower P/E of 61.7x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ASTH
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+89.9%
Fair Value
$188.57
Current Price
$37.99
$150.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 55.6% year-over-year
Earnings expanding 110.1% YoY
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
0.9% margin — thin
Operating margin of 3.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 55.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 61.7x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while ASTH is a hypergrowth play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.99 — expect wider price swings.
ASTH is growing revenue faster at 55.6% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100) and 12.4% revenue growth. ASTH offers better value entry with a 89.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?